轻中度哮喘患者对症状驱动与规律预防治疗的偏好:PRACTICAL随机试验结果
PRACTICAL随机试验的亚组调查显示,306/407名符合条件的轻中度哮喘患者完成了治疗偏好问卷。随机接受按需布地奈德-福莫特罗的患者中90%偏好该方案,而随机接受维持布地奈德的患者中仅40%偏好按需方案。多数患者偏好其实际体验过的方案,且对按需皮质类固醇-福莫特罗治疗的偏好更强。
要点
- 按需布地奈德-福莫特罗组90%偏好该方案,维持布地奈德组仅40%偏好按需方案。
- 患者偏好与实际体验的方案强烈相关,体验过按需方案者更倾向选择它。
- 所有研究吸入器的满意度均较高,按需组92%对作为缓解药使用有信心。
核心结论
- 多数患者偏好其随机分配并实际体验过的治疗方案,且对按需皮质类固醇-福莫特罗治疗的偏好更强。
研究设计与样本
- PRACTICAL随机对照试验的亚组调查,比较按需布地奈德-福莫特罗与维持布地奈德加按需特布他林。
- 407名符合条件者中306名(75%)在最终访视时完成治疗偏好、满意度、信念及体验问卷。
主要发现
- 随机接受按需布地奈德-福莫特罗的150例中135例(90%,95%CI 85.2-94.8%)偏好联合预防-缓解按需治疗。
- 随机接受维持布地奈德的156例中63例(40%,95%CI 32.7-48.1%)偏好联合预防-缓解按需治疗。
- 随机接受按需布地奈德-福莫特罗的150例中15例(10%)偏好每日两次预防吸入加按需缓解吸入。
- 随机接受维持布地奈德的156例中93例(60%)偏好每日两次预防吸入加按需缓解吸入。
- 按需布地奈德-福莫特罗组92%(n=138)在研究结束时对将其作为缓解药使用有信心。
关键数值与推荐
- 联合预防-缓解按需治疗偏好率:按需布地奈德-福莫特罗组90%(95%CI 85.2-94.8%),维持布地奈德组40%(95%CI 32.7-48.1%)。
- 每日两次预防吸入加按需缓解吸入偏好率:按需布地奈德-福莫特罗组10%,维持布地奈德组60%。
- 所有研究吸入器满意度均高;按需布地奈德-福莫特罗组92%(n=138)对作为缓解药使用有信心。
临床怎么用
- 临床沟通中应告知轻中度哮喘患者按需皮质类固醇-福莫特罗方案,体验过该方案者偏好率更高。
- 患者对治疗方案的偏好与其实际体验密切相关,共享决策时可参考偏好数据。
局限性
- 为PRACTICAL试验的亚组调查,完成问卷者占符合条件者的75%,可能存在选择偏倚。
- 偏好与随机治疗强烈相关,难以区分真实偏好与体验效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Symptom-driven low-dose inhaled corticosteroid-formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen.A subgroup of participants in the PRACTICAL study (ACTRN12616000377437), a randomised controlled trial comparing symptom-driven budesonide-formoterol with maintenance budesonide plus as-needed terbutaline completed a survey on treatment preferences, satisfaction, beliefs and experience at their final study visit.306 (75%) out of 407 eligible participants completed the survey. Regimen preference was strongly associated with randomised treatment, as were preferences for and beliefs about preventer inhaler use. Combination preventer and reliever as-needed therapy was preferred by 135 (90%, 95% CI 85.2-94.8%) out of 150 who were randomised to as-needed budesonide-formoterol, and by 63 (40%, 95% CI 32.7-48.1%) out of 156 who were randomised to maintenance budesonide. By contrast, twice-daily preventer inhaler with a reliever inhaler as required was preferred by 15 (10%) out of 150 of those randomised to as-needed budesonide-formoterol and 93 (60%) out of 156 of those randomised to maintenance budesonide. Satisfaction with all study inhalers was high. Of patients randomised to as-needed budesonide-formoterol 92% (n=138) were confident using it as a reliever at the end of the study.Although most participants preferred the regimen to which they had been randomised, this association was much stronger for those randomised to budesonide-formoterol as needed, indicating that most patients preferred as-needed corticosteroid-formoterol therapy if they had experienced it.
引用
- Baggott C, Reddel HK, Hardy J, et al. Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial. Eur Respir J. 2020. PMID: 32029450. doi:10.1183/13993003.02073-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。